Amgen hunts for deals of all sizes to combat forthcoming sales decline

A couple Big Pharma players have come out against megamergers in recent weeks. But Amgen isn’t one of them. On Tuesday’s Q4 earnings conference call, CEO Bob Bradway said his company continues to “look across the waterfront of smaller and larger deals.”